Whalesbook
Naye Funding Round mein ₹5,000 Cr Ka Valuation?
Marengo Asia Hospitals ne ek solid plan banaya hai. Wo apne business ko badhane ke liye ₹500 crore ki fundraising karne wale hain aur iske liye company ka valuation ₹5,000 crore set kiya gaya hai. Is deal mein company apna 10% stake sell kar sakti hai. Samara Capital, Godrej family office, aur Havells promoter family office jaise current investors bhi ismein support kar rahe hain. Agar ye valuation final hua, toh company ki FY25-26 ki ₹1,200 crore revenue ke hisaab se Price-to-Sales ratio lagbhag 4.17x hoga. Transaction manage karne ke liye Avendus Capital ko appoint kiya gaya hai, aur focus sovereign wealth funds aur specialized healthcare investors par hai.
Acquisitions Aur International Expansion Ka Plan
Marengo ka growth strategy based hai 'aggregation model' par, matlab wo chhote-chhote healthcare facilities ko acquire kar rahe hain. October 2020 se ab tak, unhone 8 hospitals acquire kiye hain, jismein total 2,500 beds hain. Ye hospitals India mein NCR, Gujarat, aur Rajasthan mein hain. Aur surprise baat, unka business Saudi Arabia mein bhi extend ho raha hai! Saudi Arabia apne Vision 2030 plan ke hisaab se healthcare sector mein private investment badha raha hai, jiska market value $67 billion (2024) hai. Wahan 2030 tak 27,000 aur hospital beds ki zaroorat padegi. Marengo ab Rajasthan aur Maharashtra mein aur acquisitions karne ka soch rahi hai.
Industry Valuation Aur Investment Trends Ko Samjho
Indian healthcare sector mein paisa toh khoob aa raha hai. 2022 se 2024 ke beech hospitals mein private equity se lagbhag ₹43,310 crore invest hue hain. Bade listed hospital chains jaise Apollo Hospitals aur Max Healthcare ka P/E ratio 59-63x ke aas paas hai, aur Fortis Healthcare ka 68x hai. Max Healthcare ki FY24 revenue ₹5,437 crore thi aur wo EV/EBITDA multiples par 30-35x trade karte hain. Marengo ka target valuation, current revenue scale ko dekhte hue, thoda ambitious lag sakta hai, khas kar jab compare karte hain bade players ke EBITDA multiples se.
Valuation Par Sawal Aur Potential Risks
Marengo ka ₹5,000 crore valuation zarur thoda tease kar raha hai. Haalanki unki revenue ₹1,200 crore hai, unki profitability metrics jaise EBITDA margins public nahi hain. Agar listed chains 30-35x EV/EBITDA par trade kar rahi hain, toh Marengo ka valuation ya toh bahut zyada expected EBITDA dikhata hai ya fir current scale par premium hai. Acquisition strategy se growth toh fast hoti hai, par alag-alag facilities ko integrate karne mein issues aa sakte hain aur quality maintain karna ek challenge ho sakta hai. Saudi Arabia mein operate karna growth dega, par geopolitical aur regulatory complexities bhi hain. India mein bhi price caps jaise regulatory risks margins ko affect kar sakte hain. Overall, execution risk toh hai hi.
Future Outlook Aur Challenges
Ye ₹500 crore ki funding Marengo ko aur tezi se grow karne mein help karegi, jisse wo aur acquisitions kar sakenge aur Rajasthan, Maharashtra jaise regions mein expand ho sakenge. India ka healthcare sector aage 3-5 saal mein 12% CAGR se grow hone ka estimate hai, jismein insurance coverage badhna, middle class ka rise, aur chronic diseases ki badhotri factors hain. Lekin, market mein capacity badhne se absorption kam hone ka risk, aur complex regulations bhi challenges hain. Investors dekhenge ki Marengo apne valuation aur expansion plans ko consistent profits aur market leadership mein kaise badalti hai.